PBAC's latest decision on Treprostinil sodium: Recommended (2005). Considered for treatment of primary pulmonary arterial hypertension or pulmonary arterial hypertension associated with connective tissue disease, in patients with disease of WHO Functional Class III or IV severity.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2005
Submissions
1
2005 → 2005
Eligible population
patients with primary pulmonary arterial hypertension or pulmonary arterial hypertension associated with connective tissue disease, in patients with disease of WHO Functional Class III or IV severity
Therapy area
Cardiovascular
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
6-minute walk test, survival
Key trials
P01:04 and P01:05, Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Bosentan therapy for pulmonary arterial hypertension. Inhaled iloprost for severe pulmonary hypertension
Comparator
bosentan
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis conducted; no ICER calculated by design